Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by CSL Behring (Australia) Pty Ltd

Administered by Department of Health, Disability and Ageing

Legislation au C2015G01444 In force Gazette

Legislation content

COMMONWEALTH OF AUSTRALIA

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

Sections 14 and 14A Notice

On 20 July 2015, a delegate of the Secretary of the Department of Health, on the application of           CSL Behring (Australia) Pty Ltd, consented under sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) to the supply of

  • human prothrombin complex (BERIPLEX P/N) 500 IU powder for injection vial

[AUST R 156459]

  • human prothrombin complex (BERIPLEX P/N) 1000 IU powder for injection vial

[AUST R 228338]

 

that do not conform with the requirements of paragraphs 3(5)(b) and 3(2)(l) of the Therapeutic Goods Order No 69 – General requirements for labels for medicines, in that the name and address of the sponsor on the container vial label and the name and quantity of each excipient in the goods on both the carton and container labels could not be included without sacrificing legibility.

The consent is effective from the 20 July 2015 until further notice.

 

 

 

 

 

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.